Schering buys new contraception delivery methods
This article was originally published in Clinica
German pharmaceutical and contrast media manufacturer Schering is to purchase Leiras for DM 466 million ($307 million). The subsidiary of Finnish company Huhtamaki, Leiras manufactures gynaecology, oncology and ophthalmology products and had revenues of $190 million last year. The ophthalmology business is not part of the purchase and will be sold separately later this year.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.